These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 23160205)

  • 1. Immunology beats cancer: a blueprint for successful translation.
    Pardoll DM
    Nat Immunol; 2012 Dec; 13(12):1129-32. PubMed ID: 23160205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy at large: Balancing tumor immunity and inflammatory pathology.
    Dranoff G
    Nat Med; 2013 Sep; 19(9):1100-1. PubMed ID: 24013749
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer's off switch.
    Wolchok JD
    Sci Am; 2014 May; 310(5):40-5. PubMed ID: 24783590
    [No Abstract]   [Full Text] [Related]  

  • 4. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
    Perez-Ruiz E; Minute L; Otano I; Alvarez M; Ochoa MC; Belsue V; de Andrea C; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Llacer C; Alvarez M; de Luque V; Molina C; Teijeira A; Berraondo P; Melero I
    Nature; 2019 May; 569(7756):428-432. PubMed ID: 31043740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
    Willsmore ZN; Coumbe BGT; Crescioli S; Reci S; Gupta A; Harris RJ; Chenoweth A; Chauhan J; Bax HJ; McCraw A; Cheung A; Osborn G; Hoffmann RM; Nakamura M; Laddach R; Geh JLC; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Josephs DH; Papa S; Lacy KE; Karagiannis SN
    Eur J Immunol; 2021 Mar; 51(3):544-556. PubMed ID: 33450785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immuno-regulatory antibodies for the treatment of cancer.
    Honeychurch J; Cheadle EJ; Dovedi SJ; Illidge TM
    Expert Opin Biol Ther; 2015 Jun; 15(6):787-801. PubMed ID: 25882106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seminal immunologic discoveries with direct clinical implications: The 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy.
    Ljunggren HG; Jonsson R; Höglund P
    Scand J Immunol; 2018 Dec; 88(6):e12731. PubMed ID: 30485497
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune checkpoint blockade.
    Naidoo J; Page DB; Wolchok JD
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breakthrough of the year 2013. Cancer immunotherapy.
    Couzin-Frankel J
    Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
    [No Abstract]   [Full Text] [Related]  

  • 12. Update on the current revolution in cancer immunotherapy.
    Renrick AN; Dunbar ZT; Shanker A
    Immunotherapy; 2019 Jan; 11(1):15-20. PubMed ID: 30702010
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
    Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies.
    Jacob JA
    JAMA; 2015 Nov; 314(20):2117-9. PubMed ID: 26599172
    [No Abstract]   [Full Text] [Related]  

  • 16. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop.
    Berraondo P; Ochoa MC; Rodriguez-Ruiz ME; Minute L; Lasarte JJ; Melero I
    Cancer Res; 2016 May; 76(10):2863-7. PubMed ID: 27308833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 and PD-L1 antibodies for melanoma.
    Tsai KK; Zarzoso I; Daud AI
    Hum Vaccin Immunother; 2014; 10(11):3111-6. PubMed ID: 25625924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.
    Zhao Y; Yang W; Huang Y; Cui R; Li X; Li B
    Cell Physiol Biochem; 2018; 47(2):721-734. PubMed ID: 29794465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
    Friedman CF; Postow MA
    Curr Oncol Rep; 2016 Apr; 18(4):21. PubMed ID: 26922327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.